T he new millennium brought much change to the world of esophageal motility: major changes in instrumentation, diagnostic algorithms, and therapeutics. Basically, if you have an old book, you can throw it away. High-resolution manometry (HRM) is now firmly ensconced in the clinical paradigm, with the Chicago Classification (CC) v3.0 1 being part of the daily dialogue. peroral endoscopic myotomy (POEM) has become the goto intervention for both achalasia and distal esophageal spasm in many leading centers. 2 Functional luminal imaging probe (FLIP) measurements are being used to calibrate therapeutic interventions and to provide alternative diagnostic criteria in equivocal HRM cases. 3 Then there is the opiate epidemic, creating a new family of syndromes that we are only beginning to appreciate. 4 None of this existed a decade ago. It is from this landscape that we write this Perspective.
Contemplating the evolution of motility diagnostics, HRM has proven to be a truly disruptive technology, fostering a series of innovations and revelations. The most fundamental innovation was changing the presentation format of motility data from line tracings to pressure topography plots. Alternatively called isobaric contour plots or Clouse Plots, 5, 6 pressure topography plots use a coordinate system of time on the x-axis, sensor position on the y-axis, and pressure values as spectral color within that grid. Apart from elegantly condensing an enormous dataset into a single image, key advantages of this format are that it makes sphincters, propagated or nonpropagated contractions, luminal pressure gradients, and isobaric regions within the esophagus visually obvious and easily interrogated with software tools. Hence, in a way that was never achieved with conventional manometry, HRM revealed clinically important patterns of obstructive physiology both at the esophagogastric junction (EGJ) and along the esophageal lumen. Although understanding its full relevance is still a work in progress, the concept of obstructive physiology as a fundamental abnormality of esophageal motility disorders has already substantially morphed their clinical management.
plots: the integrated relaxation pressure (IRP), the distal contractile integral (DCI), and the distal latency (DL). 1 From the beginning of the CC, it was proposed that the analysis of HRM studies be hierarchical, beginning at the EGJ and proceeding proximally. This was in recognition of the fundamental importance of outflow obstruction, manifest by an IRP greater than the upper limit of normal, as a driver of symptoms and a determinant of proximal contractility. The hallmark disease with EGJ outflow obstruction is achalasia, defined by the combination of impaired lower esophageal sphincter (LES) relaxation and absent peristalsis. However, it has since become clear that obstructive physiology occurs in several syndromes besides classic achalasia. 7 In fact, obstructive physiology can be a function of the EGJ, the distal esophagus, or both.
Obstructive physiology is a fundamental abnormality in esophageal motility disorders, potentially leading to the perception of pain and/or dysphagia. Why this occurs involves understanding how the peristaltic sequence couples with the EGJ to mediate bolus transit. Conceptually, esophageal transport can be deconstructed into a 4-phase process: phase 1, accommodation, during which the esophagus accepts the bolus as it is expelled from the oropharynx; phase 2, compartmentalization of the bolus into the distal esophagus (beyond the transition zone) by medullary-programmed peristalsis of the proximal esophagus; phase 3, esophageal emptying, largely mediated by post-transition zone myenteric plexus programmed esophageal peristalsis; and phase 4, ampullary emptying, during which the elongated, effaced, and axially displaced LES is restored to its closed, shortened, intra-hiatal state. 8 As such, inhibition is as much a part of peristalsis as is contraction. Highlighting this, studies measuring intrabolus pressure synchronized with fluoroscopy during normal peristalsis demonstrate that during phase 2, distal esophageal intrabolus pressure actually decreases as the luminal diameter increases. This is in sharp contrast to the compartmentalized pressurization of even panesophageal pressurization that is so characteristic of the major esophageal motility disorders. With achalasia, the defining physiology necessarily includes EGJ outflow obstruction but may or may not be accompanied by obstructive esophageal contractions. 9 With distal esophageal spasm (DES) and hypercontractility (jackhammer esophagus), the defining physiology necessarily involves obstructive esophageal contractions, but these may or may not be associated with EGJ outflow obstruction (Figure 1 ). In the case of DES, the obstructive characteristic of esophageal contractions is that they are premature, occurring with a DL of <4.5 seconds in the time window that should be dominated by deglutitive inhibition. 10 In the case of hypercontractility, the obstructive characteristic is that there is prolonged, concurrent contraction of essentially the entire smooth muscle segment, delaying the normal post-peristaltic recovery. Figure 1 is a conceptual graphic of the defining features of esophageal motility disorders. However, the clinical challenge is in translating the conceptual into a diagnosis on a case-by-case basis. When doing so, one can encounter numerous technical and technological challenges including the performance characteristics of specific instrumentation, technically limited studies, patient intolerance of testing, skill level of the individual conducting the test, and "borderline" diagnoses. Each of these issues is deserving of a treatise in its own right, and all speak to the need for flexibility on the part of the practitioner in their approach to difficult cases.
11 Easy cases will always be easy, but no matter what your degree of sophistication, there will always be cases in which clinical judgment ends up the final arbiter. For a detailed discussion of many of the technical challenges of HRM interpretation, the reader is referred to a recent expert consensus on the topic. 7 Pertinent to this discussion, suffice it to say that as much as HRM has advanced the science of motility testing, it has also exposed several fundamental limitations. High on this list is that there are no biomarkers of esophageal motility disorders, and even though the underlying pathology is of a myenteric plexopathy in some cases, 12 the diagnosis is not established by neuropathology. Rather, the diagnosis is established by using physiological tests to implicate abnormal neuromuscular function as the cause of symptomatic dysfunction. 13 Consequently, using HRM as the gold standard for diagnosis has inherent limitations: (1) there are always exceptions to the numeric thresholds of abnormality for the IRP, DCI, and DL; (2) other disease entities (and chronic opiate exposure) can mimic the neuromuscular dysfunction seen in esophageal motility disorders; (3) the distinction between several diagnostic entities in the CC (eg, types I and II achalasia, type III achalasia, and DES, absent contractility and end-stage achalasia) is gray rather than black and white; (4) motility disorders evolve over an undefined time span at an undefined rate, leaving open the possibility of disease in evolution; and (5) HRM is inherently better at quantifying contraction than detecting impaired inhibition, an equally important determinant of motility disorders. Finally, it needs mentioning that esophageal dysmotility often does not explain dysphagia, and hence, HRM will not identify the cause of dysphagia in such patients.
Clarifying the Gray Zones: Provocative Stimuli and Ancillary Tests
Among potential findings in HRM studies, the detection of obstructive physiology at the EGJ is the most fundamental because it is ultimately the best therapeutic target. In the CC this is based on detection of an elevated IRP. However, no metric or technology has perfect sensitivity and specificity for detecting relevant sphincter dysfunction, and in marginal or atypical cases one has to consider all available evidence, including other studies and other metrics. There are clearly cases of achalasia with an IRP <15 mmHg, particularly in type I or advanced disease, 14 and there are clearly instances in which the IRP is >15 that are not achalasia. 15 Some have proposed addressing this by lowering the threshold IRP cutoff for defining type I achalasia, 16 but ultimately that only challenges the specificity of the metric because there are published cases of achalasia with IRP values as low as 3-5 mmHg.
14 Hence, in equivocal cases or when there are conflicting findings, the International Working Group on High-Resolution Manometry instead proposed to leave open the uncertainty of an achalasia diagnosis and look for supporting evidence of functionally significant esophageal outflow obstruction. 1 This can be by demonstrating compartmentalized pressurization above the EGJ during test swallows, or it can be the demonstration of esophageal pressurization during multiple rapid swallows or rapid drink challenge, 2 provocative tests of the integrity of deglutitive inhibition. With multiple rapid swallows, five 2-mL swallows are taken less than 4 seconds apart, 17, 18 and with the rapid drink challenge, 200 mL water is swallowed within 30 seconds. 19, 20 By providing a prolonged inhibitory stimulus, multiple rapid swallows are helpful in demonstrating the integrity of deglutitive inhibition in the distal esophagus, LES relaxation, and peristaltic reserve after the termination of the sequence. 21 The rapid drink challenge is most helpful by eliciting panesophageal pressurization, indicative of obstructive physiology at the EGJ.
Another approach to clarifying inconclusive HRM findings is to invoke ancillary tests to elicit abnormal function. The simplest of these is the timed barium esophagram wherein the patient drinks 200 mL lowdensity barium over 1 minute in an upright posture, followed by frontal x-rays 1, 2, and 5 minutes afterward. The degree of esophageal emptying is then estimated by measuring the height of the residual barium column in the esophagus. The most robust outcome measure of the timed barium esophagram is the height of the barium column at 5 minutes, with the proposed critical threshold ranging from 2 to 5 cm. 22, 23 When a 12-mm barium tablet is used in conjunction with the timed barium esophagram, a secondary criterion of abnormality is for the tablet to become lodged at the EGJ. A positive timed barium esophagram is strong supportive evidence of functionally significant EGJ outflow obstruction, and a completely normal study makes an achalasia diagnosis highly unlikely. 23 Analogous data can be obtained by using high-resolution impedance manometry in an upright posture and using the impedance electrodes to ascertain the height of retained fluid in the esophagus at a 5-minute interval. 24 However, these tests are not very useful in clarifying the significance of EGJ outflow obstruction with preserved peristalsis because bolus clearance is often uncompromised in that condition.
An alternative investigation for clarifying the significance of EGJ outflow obstruction is with the FLIP device (Medtronic, Shoreview MN). The concept of the FLIP is to measure the distensibility of the EGJ during volumetric distention. This is achieved with a transorally positioned FLIP probe incorporating 16 closely spaced impedance electrodes within a compliant bag. With measured volumes of conductive saline distending the bag (and distal esophagus), an electrical current runs between adjacent impedance electrodes proportionate in amperage to the cross-sectional area of the esophageal lumen separating the electrodes (impedance planimetry). The result is an 8-to 16-cm high-resolution measurement of luminal cross-sectional area, represented on screen as a cylinder of varying diameter surrounding the FLIP probe. When combined with measurement of the intra-bag pressure, an EGJ distensibility index (mm 2 /mmHg) can be calculated. 25 The conceptual advantage of the FLIP device over HRM lies in the distinction between sphincter relaxation and sphincter opening. HRM measures relaxation; the FLIP quantifies opening. Although these are usually related, it is sphincter opening that determines the volume of bolus flow through the EGJ. The EGJ distensibility index has been reported to be low in untreated achalasia patients and in patients with poor symptomatic outcomes after achalasia treatment by using a cutoff value of 2.8 mm 2 /mmHg. 26 The FLIP can also assess esophageal motility during endoscopy by using an emerging technology, Panometry. 3, 27 Panometry involves the secondary processing of FLIP data into topographic plots of esophageal regional diameter changes versus time. As such, esophageal contractions can be detected with Panometry, even when they are not lumen occluding and, hence, undetectable by HRM. 3 The Panometry pattern commonly observed among controls and patients with normal peristalsis is of repetitive antegrade contractions, likely indicative of secondary peristalsis in response to sustained esophageal distention. In addition, a unique distention-induced contractile pattern, repetitive retrograde contractions, is commonly observed among patients with distal esophageal obstructive physiology and only rarely, if ever, seen among asymptomatic controls (Figure 2) . First described in patients with type III (spastic) achalasia, repetitive retrograde contractions have subsequently been reported among patients with non-spastic achalasia, jackhammer esophagus, eosinophilic esophagitis, reflux, and secondary hypercontractility in post-fundoplication dysphagia. 27, 28 The emerging concept is that repetitive retrograde contractions are indicative of ganglionic neural imbalance and spastic-type motility in the distal esophagus, a manifestation of either impaired nitrergic input and premature contractions (eg, type III achalasia) or augmented cholinergic input with hypercontractility and/or impaired deglutitive inhibition (eg, jackhammer esophagus). 28 In summary, despite being the best available single test for demonstrating abnormal esophageal physiology, HRM findings can be equivocal or negative despite strong clinical suspicion to the contrary. In such instances, the clinician needs to investigate further with provocative maneuvers or ancillary tests. The ultimate objective is to identify and localize clinically relevant obstructive physiology, recognizing that this can be limited to the EGJ or involve both the EGJ and the distal esophagus. Making this distinction has important management implications. Table 1 summarizes the HRM maneuvers and ancillary tests that have been reported to help with this decisionmaking.
A New Perspective on Management: Phenotype-Directed Treatment
The ideal therapy for an esophageal motility disorder would revert swallow function to normal, render the patient symptom free, and not result in pathologic reflux. No current therapy for any of the esophageal motility disorders achieves all of these objectives, and that is unlikely to change in the foreseeable future. Furthermore, the controlled treatment data currently available lag well behind recent advances in diagnostics. Indeed, although the original description of achalasia phenotypes noted that an important distinction among phenotypes was in the differential likelihood that they would respond to achalasia treatments (best outcomes in type II and worst in type III), 6 essentially all available controlled trials have not specified achalasia subtype. Retrospective analyses of randomized 29 and nonrandomized treatment series 30, 31 have, however, confirmed the original observation of differential response rates. Furthermore, with the recognition of obstructive physiology at the EGJ or distal esophagus being important foci of treatment, several disease entities beyond classic achalasia are now being rendered treatments formerly reserved for achalasia. 2 This is particularly relevant with the widespread adoption of the POEM procedure. Not only does POEM provide an option for surgical LES myotomy with reduced operative morbidity, but it also facilitates a calibrated myotomy, potentially extending proximally to include the entire smooth muscle segment of the esophagus. Together, these developments modified treatment aims to target obstructive physiology at the EGJ or distal esophagus as identified by physiologic testing, regardless of the specific disease entity.
The concept of phenotype-directed therapy is especially relevant with type III achalasia, characterized by obstructive contractility of the distal esophagus and noted to have less robust outcomes with therapies limited to the LES. 6, [29] [30] [31] Seeking to improve on this, uncontrolled series have applied POEM to type III achalasia and gauged the length of myotomy by the length of the spastic segment seen on HRM, esophageal wall thickening on imaging studies, or intraoperative FLIP. A recent meta-analysis of these uncontrolled POEM series reported a weighted pooled response rate of 92% (confidence interval, 84%-96%) in type III achalasia, with a myotomy length ranging from 13 to 19.7 cm. 32 Similarly, a retrospective analysis comparing treatment outcomes with laparoscopic Heller myotomy (LHM) and POEM in a 49-patient multicenter analysis found POEM to be significantly more efficacious (98.0 % vs 80.8 %; P ¼ .01), presumably on account of the more extensive myotomy that was done (16 vs 8 cm; P < .01). 33 Moreover, what is effective for type III achalasia should also be effective for the other esophageal motility disorders in Figure 1 characterized by obstructive physiology of the smooth muscle esophagus, DES, and jackhammer esophagus. The same POEM meta-analysis that analyzed type III achalasia outcomes reported a weighted pooled response rate to POEM of 72% (confidence interval, 55%-83%) in jackhammer and 88% in DES (confidence interval, 61%-97%). 32 Notably, the DES response rate was only 4% less than that seen in type III achalasia, emphasizing the similarity of these entities when defined according to the CC.
At the other end of the treatment spectrum is type II achalasia, wherein there is extreme obstructive physiology at the EGJ resulting in panesophageal pressurization with test swallows, but often remnants of normal peristalsis in the distal esophagus that become evident after treatment. 34 Hence, any treatment that relieved EGJ outflow obstruction, even if limited to the EGJ as in the case of pneumatic dilation (PD), should be effective. Consistent with that hypothesis, type II achalasia patients obtained the best treatment outcome in all of the type-specific analyses to date, regardless of the treatment. Indeed, in the European achalasia trial, which was a randomized controlled trial of PD vs LHM, 35 ,36 the efficacy of PD for treating type II achalasia was 100% (acknowledging acceptance of intermittent repeat PD). 29 Considering that the cost of PD is substantially less than that of LHM and that the risk of perforation between techniques is comparable (about 1% in expert hands), 37 this argues for PD as preferable to LHM in the initial treatment of type II achalasia.
Evident from the preceding discussion, the optimal initial achalasia treatment likely depends on the subtype, and cogent arguments can be made for POEM, LHM, and PD, all of which are relatively durable treatment options. Among these the most extensive literature, recently summarized by Pandolfino and Gawron, 38 has compared PD with LHM and concluded that both are highly efficacious, albeit best when done in expert hands. On the other hand, uncontrolled outcome data have been very promising comparing POEM with LHM. 2, 39 It is true that POEM is relatively new, but with the pioneering Japanese center recently summarizing their experience gleaned from their first 1000 POEM procedures, 40 one can hardly classify it as experimental. However, controlled data comparing POEM with either LHM or PD are still very limited. Although some are in progress, no randomized trial has yet been reported comparing POEM with LHM, and only one, reported as an abstract (and now a manuscript in review), has compared POEM with PD 41 (Table 2) . A recent systematic review and meta-analysis of trials comparing POEM (1958 patients) with LHM (5834 patients) reported POEM to be more effective in relieving dysphagia (mean follow-up of 16 months) but also more likely to lead to post-procedure reflux (odds ratio of 9.31 for erosive esophagitis). 42 The multicenter randomized controlled trial comparing POEM with PD in 133 treatment-naive achalasia patients reported 92% remission after 1-year follow-up in the POEM cohort compared with 70% in the PD cohort (P < .01). 41 One perforation occurred after PD, and no severe adverse events occurred related to POEM. Endoscopy 1 year after treatment found reflux esophagitis in 48% of the POEM patients (40.0% Los Angeles A or B, 8.3% C or D) compared with 13% of the PD patients (all Los Angeles A or B, P ¼ .02). In summary, PD, LHM, and POEM can all be highly efficacious treatments for achalasia, but circumstances of local expertise, achalasia subtype, and patient-specific variables (comorbidities, hiatal hernia, epiphrenic diverticulum) may make one treatment preferable to another. 43, 44 The reported success rates of PD are particularly variable among centers, with 2-year response rates ranging from 54% to 86% in 2 recent randomized controlled trials, 35, 41 likely reflective of what constituted a "success" in each trial and balancing the aggressiveness of the dilation protocol against the associated risk of sustaining a perforation.
Esophagogastric Junction Outflow Obstruction
In addition to the 3 subtypes of achalasia, CC v3.0 recognizes EGJ outflow obstruction as another entity characterized by EGJ obstructive physiology. With this entity, the IRP is greater than the upper limit of normal, but there is fragmented or even normal peristalsis such that criteria for achalasia are not met. From its initial description, EGJ outflow obstruction was reported to be a heterogeneous group, only some of whom benefitted from achalasia treatments. 15 Potential etiologies include incompletely expressed or early achalasia, esophageal wall stiffness from an infiltrative disease or cancer, eosinophilic esophagitis, extrinsic vascular obstruction, sliding or paraesophageal hiatal hernia, abdominal obesity, opiate effect, 45 or simply a false-positive measurement. Consequently, further clinical evaluation (eg, endoscopic ultrasound, FLIP, computed tomography) and a cautious approach to treatment are requisite. Indeed, 4 recent series of EGJ outflow obstruction found many cases that were minimally symptomatic or asymptomatic and that the condition resolved spontaneously 20%-40% of the time. [46] [47] [48] [49] Nonetheless, 12%-40% of them ended up being treated as achalasia, albeit conservatively.
Conclusions
High-resolution manometry and the CC have led to a major restructuring in the classification of esophageal motility disorders. Along with this has come the recognition that a defining feature of the major esophageal motility disorders is obstructive physiology, whether the EGJ, the distal esophagus, or both (Figure 1 ). Although the CC has helped crystallize esophageal motility diagnoses, especially the varied phenotypes of achalasia, it has also led to the realization that there are circumstances beyond types I, II, and III achalasia in which therapies once reserved for achalasia are beneficial. Furthermore, because no HRM pattern or metric is absolutely sensitive or specific for idiopathic achalasia, complementary assessments with provocative maneuvers during HRM or interrogating the EGJ with the FLIP during endoscopy can be useful in clarifying equivocal or inexplicable HRM findings. The emerging methodology of FLIP Panometry (Figure 2 ) is also promising in this regard. Recognizing obstructive physiology as a primary target of therapy has become particularly relevant with the development of a minimally invasive technique for performing a calibrated myotomy of the esophageal circular muscle, the POEM procedure. With the widespread adoption of POEM, there has come a shift in management strategy toward rendering treatment in a phenotypespecific manner, eg, POEM calibrated to patient-specific physiology as defined by HRM for the spastic disorders and PD for the disorders limited to the LES. Table 2 details important treatment considerations for therapeutic interventions for the major esophageal motility disorders as defined by CC v3.0 from the perspectives of the authors. Clearly, there are substantial limitations to the current data set in defining the optimal treatment for esophageal motility disorders as currently conceptualized, and there are often major issues with the available expertise, but all things being equal, this is what we glean from the best evidence currently available.
